Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 13/20 | 1.00 |
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSK | P43235 | 6/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 1.00 |
| ▸ | ELANE | P08246 | 2/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | CMA1 | P23946 | 1/20 | 1.00 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.90 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telaprevir SCHEMBL184177 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL19187546 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201921 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219678 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219647 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201959 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201901 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219193 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171584 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171583 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372846-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | claimed |
| US-20120088740-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-12 | — | — | US | claimed |
| US-8039475-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | claimed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250281456-A1 | METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-09-11 | — | — | US | disclosed |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LLC (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024055886-A1 | BRANCHED POLYETHYLENE GLYCOL LINKER AND USE THEREOF | 辽宁键凯科技有限公司 | 2024-03-21 | — | — | WO | disclosed |
| US-20230201237-A1 | RESPONSE-GUIDED HCV THERAPY | EMORY UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005042020-A2 | COMBINATIONS FOR HCV TREATMENT | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CTSB 44/4885CTSL 22/4885CTSK 56/4885 |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | CTSB 193/4885CTSL 65/4885CTSK 140/4885 |
| US-20250281456-A1 | METHODS OF TREATING CANCER BY INHIBITING BACTERIAL DNAK TO RESTORE ACTIVITIES OF ANTICANCER DRUGS | DCK, DTYMK, POLK | CTSB 2889/4885CTSL 3887/4885CTSK 669/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CTSB 550/4885CTSL 570/4885CTSK 859/4885 |
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | CTSB 206/4885CTSL 518/4885CTSK 370/4885 |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | ACE2, ACE, SARS1 | CTSB 31/4885CTSL 6/4885CTSK 86/4885 |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CTSB 34/4885CTSL 31/4885CTSK 120/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | CTSB 199/4885CTSL 109/4885CTSK 239/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | CTSB 3661/4885CTSL 3343/4885CTSK 3140/4885 |
| US-20230201237-A1 | RESPONSE-GUIDED HCV THERAPY | EIF2AK2, ADAR, IFNAR1 | CTSB 266/4885CTSL 218/4885CTSK 331/4885 |
| US-20120088740-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | MLX, AGXT, CYP4X1 | CTSB 4069/4885CTSL 1924/4885CTSK 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.